Biosion is a leading "In Global For Global" clinical stage biotechnology company developing innovative biologics to address resistant, relapsed and residual disease for patients worldwide. Established in 2017, Biosion has assembled a world-class team with extensive experience in global biologics development and built an oncology and auto-immune focused pipeline of innovative biologics through its internally-derived proprietary technologies, including the H3 hybridoma platform, SynAbTM synergistic antibody platform, SynTracerTM HT-endocytosis screening, and FlexibodyTM bispecific platforms. Biosion's mission is to discover and develop innovative biologics through the synergy of great science, cutting edge technologies and superior craftmanship for patients worldwide.